國家衛生研究院 NHRI:Item 3990099045/9220
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857670      線上人數 : 728
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9220


    題名: High expression of Hsp90-beta and GRP 94 association with poor survival in resected non-small cell lung cancer patients
    其他題名: High expression of Hsp90-β and GRP 94 association with poor survival in resected non-small cell lung cancer patients
    作者: Chen, SH;Kuo, CC;Li, CF;Tsou, TC;Chiang, HC;Chang, KY;Cheung, CHA;Chan, LT;Chang, JY
    貢獻者: Institute of Biotechnology and Pharmaceutical Research;National Institute of Environmental Health Sciences;National Institute of Cancer Research
    摘要: Background: Heat Shock Protein 90 (Hsp90) is an ATP-dependent molecular chaperone that was required for the stability and function of more than 200 signaling proteins that promote cancer cell growth and/or survival. It exists as multiple isoforms that includes Hsp90-alpha and Hsp90-beta in the cytoplasm and GRP94 and TRAP1 localized to the ER and mitochondria, respectively. We investigated the relationship with clinical outcome and the expression of Hsp90-beta, GRP94 in the resected non-small cell lung cancer (NSCLC) patient. Methods: We obtained surgical tissue specimens from 208 patients with NSCLC (stage IA, 40; stage IB, 57; stage IIA, 22; stage IIB, 50; stage IIIA, 27; stage IIIB, 12) who underwent surgical resection of their tumors for immunohistochemical analyses of Hsp90-beta, GRP94. Clinical characteristics, survival were analyzed according to immunohistochemical expression of Hsp90-beta, GRP94 using the χ2 test, Kaplan–Meier method, and Cox proportional hazard model. Results: No correlations were observed between the expression of Hsp90-beta, GRP94 and several clincopathological factors. In a survival analysis, the expression of Hsp90-beta was significantly related to overall survival (OS, log-rank test, p=0.021). The OS was 95.97 months (95% confidence interval[CI], 48.31~143.63) with the low expression group of Hsp90-beta, as compared with 31.6 months (95% CI, 10.58~52.62) with high expression group (hazard ratio[HR], 1.95; 95% CI, 1.08~3.48). The expression of GRP94 was also significantly related to OS(log-rank test, p=0.036). The OS was 72.43 months (95% CI, 47.58~97.29) with the low expression group of GRP94, as compared with 32.27 months (95% CI, 18.48~46.06) with high expression group (HR, 1.64; 95% CI, 1.03~2.63). Conclusions: We found that the immunohistochemically high expression of Hsp90-beta, GRP94 were independent prognostic factors for reduced survival, although further large prospective studies are needed to validate our findings.
    日期: 2014-05
    關聯: Journal of Clinical Oncology. 2014 May;32(15, Suppl.):e13522.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e13522
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000358613200222
    顯示於類別:[郭靜娟] 會議論文/會議摘要
    [鄒粹軍] 會議論文/會議摘要
    [張光裕] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要
    [張俊彥] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000358613200222.pdf53KbAdobe PDF546檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋